

compounds may be allowable if enabled and supported by the specification and no other prior art is identified.

5. Brief Identification of principal arguments:

The Applicant argued that claims are enabled based upon the disclosure of a reproducible assay for identifying a D-serine transport inhibitor that is useful for the treatment of the recited conditions and that D-serine does not anticipate the claimed invention.

6. Indication of other pertinent matters discussed: The Examiner suggested that since a final rejection has been issued Applicants may wish to file a continuation application. The Examiner also provided suggestions for claims directed to Applicant's pathway including providing a showing of novelty of the new pathway effected by D-serine transport inhibitors and that the pathway is unexpected and affecting said pathway provides unexpectedly superior results when compared to closest prior art.

7. Results of Interview: No specific agreement was reached.

It is believed that no petition or fee is required. However, if the USPTO deems otherwise, Applicant hereby petitions for any extension of time which may be required to maintain the pendency of this case, and any required fee, except for the Issue Fee, for such extension is to be charged to Deposit Account No. 19-4880.


SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Respectfully submitted,


Jennifer M. Hayes
Registration No. 40,641

Date: July 16, 2004